Trump SLASHES Drug Prices – Pharma FURIOUS!

President Donald Trump’s revival of his “most favored nation” model aims to slash Medicare drug costs by linking U.S. prices to those in other wealthy nations.

At a Glance

Trump signs executive order linking Medicare prices to international benchmarks

The 2020 version of the policy was blocked by litigation

Pharma groups warn the move threatens innovation and investment

Public support remains strong amid rising out-of-pocket drug costs

Final policy details are pending regulatory rollout

Reviving a Controversial Policy

Trump is bringing back his most aggressive health care assault yet—forcing U.S. drug prices to match the lowest in the world. His 2020 version was killed in court, but this reboot is designed to survive the legal gauntlet.

Americans pay ten times more than patients in Canada and Europe for the same meds. Trump’s plan flips the script—turning Medicare into a global price negotiator.

Watch CBS News’ report on the order at Trump’s explosive Medicare drug crackdown.

Pharma Fights Back

Drug companies are panicking. Their lobbyists now claim Trump’s move could wipe out $1 trillion in profits and destroy innovation pipelines. But voters aren’t buying it.

As NBC News confirms, three out of four Americans say they’re being ripped off—and want the government to do something about it. Trump calls it “the pill penalty”—a rigged system where Americans pay more so pharma execs can cash out.

Can It Work?
The savings could be huge. The White House projects billions in taxpayer relief if prices are finally reined in. Previous versions were expected to save $85 billion over seven years.

But legal landmines lie ahead. Trump’s 2020 plan was slapped down for bypassing public comment. This time, officials are building a bulletproof rollout—hoping to beat pharma in court.

The Political Battle Ahead

This is war: Trump vs. Big Pharma. The plan also goes after middlemen drug cartels who inflate prices behind closed doors.

Trump says it’s time to expose the racket. Whether this becomes a landmark win—or just another lawsuit showdown—depends on how hard the GOP fights to back him. One thing’s clear: drug pricing just became the biggest health issue of the 2024 race.